Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Neoplasms
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more

Conditions: Diabetes Mellitus
Interventions: Livongo Health System, iHealth Glucose Meter; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Giant Cell Arteritis
Interventions: Abatacept, Placebo, Glucocorticoid Treatment; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Fullerton, California • West Hollywood, California + 10 more

Conditions: Obesity
Interventions: Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more

Conditions: Prostate Cancer
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Large B-cell Lymphoma
Interventions: Golcadomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 46
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 38 more

Conditions: Healthy
Interventions: LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Evaluate Patient Comfort Level During Paracentesis by Numbing Skin With a Needle-less Device, Instead of Using a Needle to Numb the Skin
Interventions: Experimental J-Tip Needle-Free Injection System, Control (Standard treatment); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: AF - Atrial Fibrillation
Interventions: Pulse Field Ablation; Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hidradenitis Suppurativa
Interventions: CO2 (carbon dioxide) laser, Surgical Deroofing; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 13 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: somapacitan, somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Kidney Disease
Interventions: Allopurinol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
Interventions: IPI-549 (eganelisib), Nivolumab, Placebos; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Fort Wayne, Indiana • Baltimore, Maryland • Detroit, Michigan + 4 more

Conditions: Liver Disease, Pain
Interventions: paravertebral blocks; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Congenital Pseudarthrosis of Tibia
Interventions: NVD003, Iliac Crest Bone Graft; Biological · Procedure
Lead sponsor: Novadip Biosciences; Industry
Eligibility: Up to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Phoenix, Arizona • Loma Linda, California • Baltimore, Maryland + 1 more

Conditions: Persistent Atrial Fibrillation
Interventions: CoreMap EP Mapping System Mapping, CoreMap EP Mapping System Map-Guided Ablation; Device
Lead sponsor: CoreMap Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Naples, Florida • Burlington, Vermont • Richmond, Virginia

Conditions: Familial Adenomatous Polyposis (FAP)
Interventions: Celecoxib, Routine Medical Care; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deafness
Interventions: Everyday Clinical Listening Program (Control), ENI-Based Experimental Program 1, ENI-Based Experimental Program 2; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Behavior, Health
Interventions: Working Memory Training, Working Memory; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 11 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Flint, Michigan • Highland Park, Michigan

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 62
States / cities: Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more

Conditions: Heart Failure
Interventions: Acute exercise, Cardiac rehabilitation; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Myeloid Leukemia
Interventions: Oral Azacitidine, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Cholestasis, Prematurity, Gastroschisis, Intestinal Atresia, Necrotizing Enterocolitis
Interventions: Parenteral Nutrition; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: Up to 7 Days
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Study to Understand Gaining Access to Blood Glucose Records

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

J-Tip Use for Paracentesis in Adults With Ascites

Comparison of Two Pulse Field Ablation Systems for AF Ablation

Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing

Efficacy and Safety of GTR in Comparison to Copaxone®

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Uric Acid and the Endothelium in CKD

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Comparison Between Epidural and Bilateral Paravertebral Blocks in Liver Resection

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

Endocardial Mapping With the CoreMap EP Mapping System

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Improving Cochlear Implant Outcomes Through Modeling and Programming Strategies Based on Human Inner Ear Pathology

Train Your Brain 2.0 - Improving Memory and Decision Making Among Youth

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

Identifying Markers of Exercise Training in Heart Failure

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants